NIOX MINO enables management of airway inflammation and thus is believed to play a critical role in effective diagnosis, treatment and follow-up of patients with inflammatory airway diseases such as asthma.
According to the company, an approval is a key advancement towards receiving reimbursement for inflammation monitoring with the help of FeNO in asthma management.
The decision of the market approval in Korea was taken by Korea Food & Drug Administration (KFDA) while that in Taiwan was taken by Taiwan Food & Drug Administration (TFDA).